Novo Nordisk's pipeline, especially the oral GLP-1 and Alzheimer’s trial, offers significant long-term upside. Click here to ...

Following a visit to Copenhagen, Denmark, to collaborate on enhancing urban health, the Bangkok Metropolitan Administration (BMA) and Novo Nordisk will launch the Cities for Better Health (CBH) ...

Wegovy® is indicated for chronic weight management in adults and adolescents (12+) with obesity or overweight and at least ...

Eli Lilly (LLY 0.40%) and Novo Nordisk (NVO 1.97%) are two phenomenal growth stocks that investors probably can't go wrong ...

One in eight Americans use GLP-1 weight-loss drugs, but are they getting the real thing? Novo Nordisk's dramatic exit from a ...

Denmark's Novo Nordisk said on Tuesday it had submitted a new, higher dose of its obesity treatment Wegovy to the European ...

Novo Nordisk submits a higher 7.2 mg dose of Wegovy for EMA approval, backed by trials showing 21% weight loss in obesity and ...

Collaboration aims to develop model clinics and strengthen capacity of healthcare professionals in management of obesity ...

Analysts said the deal with Novo was likely giving Hims “‘credibility’ or increased consumer traffic,” adding that the ...

The high dose of Wegovy is one part of Novo Nordisk's plan to defend its obesity business, along with a major ...

Italian authorities on Monday appointed a special commissioner to help Danish drugmaker Novo Nordisk speedily deliver its ...

The International Organization for Migration (IOM) has partnered with the Novo Nordisk Foundation, a Danish enterprise ...